Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis

ABSTRACT Background The eradication of Helicobacter pylori ( H. pylori ) is crucial due to its rising prevalence and increasing resistance. Bismuth‐containing quadruple therapies (BcQTs) have been proposed as a viable treatment option; however, the optimal duration for it remains contentious. This systematic review and meta‐analysis aimed to compare the clinical efficacy of short‐term BcQT (defined as 7 or 10 days) with a standard 14‐day course. Methods A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted for randomized controlled trials published in English until June 20, 2024. Eligibility criteria were applied to identify relevant studies. Summary risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for the included studies regarding eradication rates, adverse effects, and compliance. This systematic review and meta‐analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and was previously registered in PROSPERO under registration number CRD42024547773. Results This meta‐analysis finally included 15 trials involving a total of 4505 patients. The eradication rates for short courses of BcQT were lower than those for the 14‐day course (RR 0.96, 95% CI 0.93–0.99). However, the eradication rate for the 10‐day therapy was comparable to that of the 14‐day therapy (RR 0.98, 95% CI 0.95–1.00). Subgroup analyses of antibiotic combinations indicated that tetracycline and metronidazole combinations yielded similar H. pylori eradication rates in the 7‐day versus the 14‐day BcQT (RR 0.93, 95% CI 0.84–1.02). In the potassium‐competitive acid blocker subgroup, the eradication rates remained similar across the 14‐day group and the short‐course treatment groups, whether evaluating the short‐term treatment groups as a whole or the 7‐ and 10‐day subgroups separately. Additionally, the adverse effects and compliance associated with the short course of BcQT were comparable to those of the 14‐day therapy. Conclusion A 10‐day course of BcQT may represent the optimal treatment duration. Nevertheless, the choice of antibiotic combination should be guided by the regional antibiotic resistance patterns of H. pylori , as combinations with lower resistance rates are more effective. Trial Registration PROSPERO number: CRD42024547773